Please use this identifier to cite or link to this item: http://repository.unmul.ac.id/handle/123456789/5725
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSoeroso, Joewono-
dc.contributor.authorIndriyanti, Niken-
dc.date.accessioned2021-01-26T04:01:22Z-
dc.date.available2021-01-26T04:01:22Z-
dc.date.issued2019-06-30-
dc.identifier.issn2407-6090-
dc.identifier.urihttp://repository.unmul.ac.id/handle/123456789/5725-
dc.description.abstractDoxycycline has non-antibiotic effects which are necessary for lupus treatment, such as immunosuppressive, anti-inflammatory, and anti-depressive effects. This widely used drug is a promising one to be developed as lupus drug since doxycycline has no data of its microbial resistance and it is safe for maternity. The other benefit is that doxycycline has lower side effects than the current drugs for lupus treatment. It gives excellent chances for women with lupus to be pregnant and have healthy babies. This article contains the compilation data of doxycycline target sites beyond its beneficial activities for lupus and also its limitations. Finally, this data will be a background for doxycycline in lupus drug development.en_US
dc.description.sponsorshipWe thank Faculty of Medicine, Universitas Airlangga for in kind contribution in providing literature access to finish this manuscript. We also thank Faculty of Pharmacy, Mulawarman University for the publication funding.en_US
dc.language.isoenen_US
dc.publisherJournal of Tropical Pharmacy and Chemistryen_US
dc.relation.ispartofseries4;5-
dc.subjectdoxycycline , non - antibiotic effects, lupus, drug development, maternityen_US
dc.titleMinireview: Prospect of Doxycycline in Systemic Lupus Erythematosus Treatment201en_US
dc.typeArticleen_US
Appears in Collections:A - Pharmacy

Files in This Item:
File Description SizeFormat 
173-Article Text-411-1-10-20190906(1).pdfFullpaper259.71 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.